BT
CTNM

Banque Transatlantique’s Contineum Therapeutics CTNM Stock Holding History

Banque Transatlantique’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.44K Hold
220
– – ﹤0.01% 474
2026
Q1 		$2.95K Hold
220
– – ﹤0.01% 406
2025
Q4 		$2.51K Buy
+220
New +$2.51K ﹤0.01% 239

Other funds holding CTNM

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Banque Transatlantique's CTNM Position: Q2 2026 in Review

Banque Transatlantique held its Contineum Therapeutics (CTNM) position steady in Q2 2026 at 220 shares worth $2.44K. The position accounts for ﹤0.01% of the portfolio, ranked #474.

Banque Transatlantique first reported a position in CTNM in Q4 2025 and has held it in 3 quarters since. The position peaked at $2.95K in Q1 2026. 102 funds tracked by Wall St. Rank hold CTNM as of Q2 2026.

  • Banque Transatlantique held 220 shares of Contineum Therapeutics worth $2.44K as of Q2 2026.
  • Banque Transatlantique left its Contineum Therapeutics share count unchanged in Q2 2026.
  • Contineum Therapeutics made up ﹤0.01% of Banque Transatlantique's portfolio in Q2 2026, its #474 holding.
  • Banque Transatlantique first reported a position in Contineum Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Banque Transatlantique's Contineum Therapeutics position peaked at $2.95K in Q1 2026.
  • 102 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q2 2026.

Based on Banque Transatlantique's 13F filing for Q2 2026, filed 30 Jul 2026.